STOCK TITAN

Vivos Therapeutics, Inc. - VVOS STOCK NEWS

Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.

Vivos Therapeutics, Inc. (symbol: VVOS) is a leading medical technology company dedicated to providing innovative solutions for patients suffering from sleep disordered breathing (SDB), particularly mild-to-moderate obstructive sleep apnea (OSA). The company specializes in the development and commercialization of proprietary treatment protocols and customized oral appliances, known collectively as the Vivos System. This non-surgical, non-invasive, and non-pharmaceutical system is designed to address craniofacial and anatomical anomalies associated with OSA, offering a cost-effective alternative to traditional treatments.

The Vivos System combines the expertise of specially trained dentists and medical professionals to deliver comprehensive care. Through its Vivos Integrated Healthcare Network, the company enables healthcare providers, including general dentists, medical doctors, myofunctional therapists, and chiropractors, to offer targeted therapies for SDB. Additionally, Vivos licenses its intellectual property to third-party manufacturers to fabricate these advanced appliance devices, expanding its reach and impact.

Recent developments at Vivos Therapeutics highlight the company's commitment to improving patient outcomes. The favorable update to United Healthcare's medical policy now endorses oral appliance therapies, potentially increasing the adoption of Vivos devices. Furthermore, the recall of numerous CPAP devices by ResMed and Philips Respironics presents a significant revenue opportunity for Vivos.

The company has also achieved a significant milestone with the introduction of the first Medicare-accepted oral appliance treatment for all severities of obstructive sleep apnea in adults. This breakthrough enhances the accessibility of effective OSA treatment to a broader patient population.

Vivos Therapeutics continues to position itself as a pioneer in the medical technology space, driven by its mission to improve the quality of life for patients with sleep-disordered breathing. Stay informed about Vivos Therapeutics' latest news and developments to understand the dynamic landscape of this innovative company.

Rhea-AI Summary
Vivos Therapeutics, Inc. reported financial results for Q2 2023, with revenue of $3.4 million, a decrease compared to Q2 2022. Gross profit was $2.1 million, and operating expenses decreased by 31% quarter over quarter and 25% year to date. The company's cost-cutting initiatives led to a reduction in net loss of 21% for Q2 2023. Vivos has treated approximately 40,000 patients with The Vivos Method and trained over 1,800 dentists. They also announced positive results from a clinical study on the treatment of migraine headaches. Vivos anticipates the need for additional financing to achieve cash flow positive operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
-
Rhea-AI Summary
Vivos Therapeutics to release Q2 2023 financial results today after market close. Conference call at 6:00 pm ET to review results and recent milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
-
Rhea-AI Summary

Vivos Therapeutics reported its financial results for Q4 and full year 2022 with revenue of $4.0 million in Q4 and $16.0 million for the full year, compared to $4.4 million and $16.9 million in the previous year. The company completed a capital raise of approximately $7.4 million in January 2023. Gross profit decreased to $2.4 million in Q4, down from $3.1 million in 2021, reflecting increased costs. Vivos also acquired patents from Advanced Facialdontics, enhancing its portfolio for treating sleep disorders. The company aims for revenue growth in 2023 through expanded product offerings and partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
Rhea-AI Summary

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is set to release its fourth quarter and full year 2022 financial results after market close on March 30, 2023. This announcement will be followed by a conference call at 5:00 PM ET to discuss the results and recent milestones. Vivos specializes in medical devices for treating sleep disorders, particularly obstructive sleep apnea (OSA) and snoring, through its proprietary oral appliances. The company has treated over 33,000 patients globally, showcasing the effectiveness of its noninvasive Vivos Method, developed by trained dentists. The company emphasizes its commitment to innovation in the sleep disorder treatment sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags

FAQ

What is the current stock price of Vivos Therapeutics (VVOS)?

The current stock price of Vivos Therapeutics (VVOS) is $4.81 as of December 24, 2024.

What is the market cap of Vivos Therapeutics (VVOS)?

The market cap of Vivos Therapeutics (VVOS) is approximately 23.3M.

What does Vivos Therapeutics, Inc. specialize in?

Vivos Therapeutics specializes in the development and commercialization of technology solutions for patients with sleep disordered breathing, including mild-to-moderate obstructive sleep apnea.

What is the Vivos System?

The Vivos System is a non-surgical, non-invasive treatment for mild-to-moderate obstructive sleep apnea, involving customized oral appliances and proprietary treatment protocols.

Who can benefit from Vivos Therapeutics' solutions?

Patients with mild-to-moderate obstructive sleep apnea (OSA) and related sleep disordered breathing conditions can benefit from Vivos Therapeutics' solutions.

How does Vivos Therapeutics collaborate with healthcare providers?

Vivos Therapeutics collaborates with healthcare providers through its Vivos Integrated Healthcare Network, enabling dentists, medical doctors, and other professionals to offer targeted treatments.

What are some recent achievements of Vivos Therapeutics?

Recent achievements include the favorable update to United Healthcare's policy supporting oral appliance therapies and the introduction of Medicare-accepted oral appliance treatment for all severities of obstructive sleep apnea.

What opportunities have arisen from the recall of CPAP devices?

The recall of CPAP devices by ResMed and Philips Respironics has created significant revenue opportunities for Vivos Therapeutics' oral appliance devices.

How does Vivos Therapeutics manufacture its oral appliances?

Vivos Therapeutics licenses its intellectual property to third-party manufacturers who fabricate the appliance devices for healthcare professionals.

What makes the Vivos System unique?

The Vivos System is unique due to its non-surgical, non-invasive, and non-pharmaceutical approach, offering a cost-effective solution for treating mild-to-moderate obstructive sleep apnea.

Who are the target customers for Vivos Therapeutics?

Target customers include general dentists, medical doctors, myofunctional therapists, chiropractors, and other healthcare providers involved in treating sleep disordered breathing.

What is the mission of Vivos Therapeutics?

The mission of Vivos Therapeutics is to improve the quality of life for patients suffering from sleep disordered breathing through innovative and effective treatment solutions.

Vivos Therapeutics, Inc.

Nasdaq:VVOS

VVOS Rankings

VVOS Stock Data

23.26M
4.59M
1.51%
13.72%
2%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
LITTLETON